Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of once-daily, single-inhaler, fixed-dose combination of mometasone/indacaterol/glycopyrronium in patients with asthma with or without persistent airflow limitation: Post hoc analysis from the IRIDIUM study.
Van Zyl-Smit RN, Kerstjens HA, Maspero JF, Kostikas K, Hosoe M, Tanase AM, D'Andrea P, Mezzi K, Brittain D, Lawrence D, Chapman KR. Van Zyl-Smit RN, et al. Among authors: tanase am. Respir Med. 2023 May;211:107172. doi: 10.1016/j.rmed.2023.107172. Epub 2023 Mar 9. Respir Med. 2023. PMID: 36906187 Free article.
Indacaterol acetate/mometasone furoate provides sustained improvements in lung function compared with salmeterol xinafoate/fluticasone propionate in patients with moderate-to-very-severe COPD: results from a Phase II randomized, double-blind 12-week study.
Beeh KM, Kirsten AM, Tanase AM, Richard A, Cao W, Hederer B, Beier J, Kornmann O, van Zyl-Smit RN. Beeh KM, et al. Among authors: tanase am. Int J Chron Obstruct Pulmon Dis. 2018 Dec 6;13:3923-3936. doi: 10.2147/COPD.S179293. eCollection 2018. Int J Chron Obstruct Pulmon Dis. 2018. PMID: 30584293 Free PMC article. Clinical Trial.
A randomized, double-blind study to compare the efficacy and safety of two doses of mometasone furoate delivered via Breezhaler® or Twisthaler® in patients with asthma.
Buhl R, Tanase AM, Hosoe M, Cao W, Demin I, Bartels C, Jauernig J, Ziegler D, Patalano F, Hederer B, Kanniess F, Tillmann HC. Buhl R, et al. Among authors: tanase am. Pulm Pharmacol Ther. 2020 Jun;62:101919. doi: 10.1016/j.pupt.2020.101919. Epub 2020 May 7. Pulm Pharmacol Ther. 2020. PMID: 32387408 Free article.
Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study.
Kerstjens HAM, Maspero J, Chapman KR, van Zyl-Smit RN, Hosoe M, Tanase AM, Lavecchia C, Pethe A, Shu X, D'Andrea P; IRIDIUM trial investigators. Kerstjens HAM, et al. Among authors: tanase am. Lancet Respir Med. 2020 Oct;8(10):1000-1012. doi: 10.1016/S2213-2600(20)30190-9. Epub 2020 Jul 9. Lancet Respir Med. 2020. PMID: 32653074 Clinical Trial.
Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, controlled phase 3 study.
van Zyl-Smit RN, Krüll M, Gessner C, Gon Y, Noga O, Richard A, de Los Reyes A, Shu X, Pethe A, Tanase AM, D'Andrea P; PALLADIUM trial investigators. van Zyl-Smit RN, et al. Among authors: tanase am. Lancet Respir Med. 2020 Oct;8(10):987-999. doi: 10.1016/S2213-2600(20)30178-8. Epub 2020 Jul 9. Lancet Respir Med. 2020. PMID: 32653075 Clinical Trial.
Pharmacokinetics of mometasone furoate delivered via two dry powder inhalers.
Vaidya S, Ziegler D, Tanase AM, Malmqvist U, Kanniess F, Hederer B, Hosoe M. Vaidya S, et al. Among authors: tanase am. Pulm Pharmacol Ther. 2021 Oct;70:102019. doi: 10.1016/j.pupt.2021.102019. Epub 2021 Mar 23. Pulm Pharmacol Ther. 2021. PMID: 33771722 Free article. Clinical Trial.
One time a day mometasone/indacaterol fixed-dose combination versus two times a day fluticasone/salmeterol in patients with inadequately controlled asthma: pooled analysis from PALLADIUM and IRIDIUM studies.
Chapman K, van Zyl-Smit R, Maspero J, Kerstjens HAM, Gon Y, Hosoe M, Tanase AM, Pethe A, Shu X, D'Andrea P. Chapman K, et al. Among authors: tanase am. BMJ Open Respir Res. 2021 Aug;8(1):e000819. doi: 10.1136/bmjresp-2020-000819. BMJ Open Respir Res. 2021. PMID: 34452934 Free PMC article.
A Review of the Unique Drug Development Strategy of Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate: A First-in-Class, Once-Daily, Single-Inhaler, Fixed-Dose Combination Treatment for Asthma.
Brittain D, D'Andrea P, Gruen E, Hosoe M, Jain D, Jauernig J, Pethe A, Scosyrev E, Tanase AM, Tillmann HC. Brittain D, et al. Among authors: tanase am. Adv Ther. 2022 Jun;39(6):2365-2378. doi: 10.1007/s12325-021-02025-w. Epub 2022 Jan 24. Adv Ther. 2022. PMID: 35072888 Free PMC article. Review.
Long-term safety of once-daily indacaterol acetate/glycopyrronium bromide/mometasone furoate high-dose, and indacaterol acetate/mometasone furoate high-dose, in Japanese patients with inadequately controlled asthma: Results from two open-label, 52-week studies.
Sagara H, D'Andrea P, Tanase AM, Pethe A, Tanaka Y, Matsuo K, Hosoe M, Nakamura Y. Sagara H, et al. Among authors: tanase am. J Asthma. 2023 Feb;60(2):403-411. doi: 10.1080/02770903.2022.2056048. Epub 2022 May 30. J Asthma. 2023. PMID: 35348408 Clinical Trial.
Mometasone/Indacaterol/Glycopyrronium (MF/IND/GLY) and MF/IND at Different MF Strengths versus Fluticasone Propionate/Salmeterol Xinafoate (FLU/SAL) and FLU/SAL+ Tiotropium in Patients with Asthma.
van Zyl-Smit RN, Chapman KR, Kerstjens HAM, Gessner C, Sagara H, Tanase AM, Hosoe M, Pethe A, Lawrence D, Tillmann HC, D'Andrea P. van Zyl-Smit RN, et al. Among authors: tanase am. J Asthma Allergy. 2023 Jan 20;16:123-134. doi: 10.2147/JAA.S392975. eCollection 2023. J Asthma Allergy. 2023. PMID: 36714049 Free PMC article. Review.
24 results